



1222-2022
800
ANNI



UNIVERSITÀ
DEGLI STUDI
DI PADOVA



39th Vicenza Course on AKI & CRRT

October 26-29, 2021

VIRTUAL MEETING

www.irriv.com - www.npsevents.it

39th Vicenza Course on AKI&CRRT

October 26	October 27	October 28	October 29
13.00 SPONSORED ACTIVITY - 30' Symposium Chairs of the day: Claudio Ronco & Marlies Ostermann LECTURE: 13.30 Critical care Nephrology: 30 year perspective <i>R. Bellomo</i>	13.00 SPONSORED ACTIVITY - 30' Symposium Chairs of the day: Claudio Ronco & Ashita Tolwani LECTURE: 13.30 Acute RRT 30 years perspective <i>R. Mehta</i>	13.00 SPONSORED ACTIVITY - 30' Symposium Chairs of the day: Claudio Ronco & Stefano Romagnoli LECTURE: 13.30 Industry and Academia: joining the forces in AKI <i>J. Kellum</i>	13.00 SPONSORED ACTIVITY - 30' Symposium Chairs of the day: Claudio Ronco & Mitchel Rosner LECTURE: 13.30 AKI Worldwide <i>J. Moura Neto</i>
Block 1: ACUTE KIDNEY INJURY	Block 4: AKI MANAGEMENT	Block 7: ORGAN CROSSTALK	Block 10: PEDIATRIC AKI & CRRT
13.45 The continuum of AKI (Definition /Classification) <i>M. Ostermann</i>	13.45 CRRT initiation: The final cut <i>M. Meersch</i>	13.45 Update on Heart-Kidney Interaction <i>A. Kazory</i>	13.45 Neonatal and pediatric AKI <i>S. Goldstein</i>
13.57 AKI epidemiology today <i>N. Pannu</i>	13.57 When do I begin in my practice <i>E. Macedo</i>	13.57 Update on Lung-Kidney interaction <i>F. Husain-Syed</i>	13.57 Update on Carpediem registry <i>E. Vidal</i>
14.09 AKI Risk modifiers and mitigators <i>K.D. Liu</i>	14.09 Can I use artificial intelligence to begin RRT? <i>K. Kashani</i>	14.09 The IRRIV Index in AKI diagnosis <i>S. Samoni</i>	14.09 Combining CRRT and ECMO <i>Z. Ricci</i>
14.21 Patterns of AKI Recovery <i>L. Forni</i>	14.21 Refining indications for RRT initiation <i>J. Prowle</i>	14.21 Update on Liver-kidney interaction <i>M. Nadim</i>	14.21 Planning a pediatric ADQI <i>R.K. Basu</i>
14.33 Transitioning from AKI to CKD <i>G. Castellano</i>	14.33 Discussion	14.33 Brain - kidney interaction <i>S. Tanaka</i>	14.33 Discussion
14.45 Discussion		14.45 Metabolism in AKI and sepsis <i>S. Huen</i>	
14.57 Discussion		14.57 Discussion	
15.00 SPONSORED ACTIVITY - 15' Meet the expert	14.45 SPONSORED ACTIVITY - 15' Meet the expert	15.10 SPONSORED ACTIVITY—15' Meet the expert	14.45 SPONSORED ACTIVITY - 15' Meet the expert
Block 2: AKI & SEPSIS	Block 5: CHOICES FOR RRT	Block 8: AKI: SPECIAL ASPECTS	Block 11: NEW TECHNIQUES IN AKI AND SEPSIS
15.15 Sepsis in 2021: What are the unresolved issues? <i>J.L. Vincent</i>	15.00 How to choose anticoagulation <i>A. Tolwani</i>	15.25 Perioperative AKI: ADQI update <i>A. Shaw</i>	15.00 Sequential extracorporeal therapy <i>S. De Rosa</i>
15.27 AKI in Sepsis: What do we need to understand? <i>E. See</i>	15.12 How to choose a membrane <i>W. Clark</i>	15.37 Thermoneutral regulation of AKI <i>L. Curtis</i>	15.12 Application of sorbents <i>T. Rimmelé</i>
15.39 Sepsis and AKI: do we have useful biomarkers? <i>A. Zarbock</i>	15.24 How to choose a technique <i>P. Murray</i>	15.49 Contrast induced AKI? <i>N. Pannu</i>	15.24 New extracorporeal blood purification techniques <i>C. Monard</i>
15.51 New options to achieve evidence in sepsis <i>C. Ince</i>	15.36 How to measure quality of performance <i>T. Mottes</i>	16.01 Discussion	15.36 Experience with sorbents in Covid-19 <i>N. Srisawat</i>
16.03 Discussion	15.48 Discussion	16.15 SPONSORED ACTIVITY - 15' Meet the expert	15.48 ET for cytokine release syndrome in CAR-T therapy <i>G. Bottari</i>
16.15 SPONSORED ACTIVITY - 15' Meet the expert	16.00 SPONSORED ACTIVITY - 15' Meet the expert	Block 9: AKI in Covid-19 (ADQI Consensus)	16.00 The ARRT registry <i>G. Villa</i>
Block 3: AKI & BIOMARKERS	Block 6: FLUID MANAGEMENT	16.30 Epidemiology of AKI in Covid-19 <i>L. Yang</i>	16.12 Discussion
16.30 Biology of AKI biomarkers <i>M. Okusa</i>	16.15 Net ultrafiltration, management and outcomes <i>R. Murugan</i>	16.42 Mechanisms of Kidney damage in SARS-CoV2 infection <i>V. Cantaluppi</i>	16.30 SPONSORED ACTIVITY - 15' Meet the expert
16.42 Role of biomarkers in AKI definition <i>M. Ostermann</i>	16.27 Fluid infusion, net UF and hemodynamics <i>R. Murugan</i>	16.54 Prevention and management <i>N. Lumlertgul</i>	Block 12: ECOS
16.54 Biomarker-guided interventions in AKI <i>A. Zarbock</i>	16.39 Fluid Balance in STARRT-AKI: a secondary analysis <i>S. Bagshaw</i>	17.06 Dialysis Applications <i>A. Vijayan</i>	16.45 The Art of decongestion in heart failure <i>A. Kazory</i>
17.06 Biomarkers and CRRT <i>R.K. Basu</i>	16.51 Artificial diuresis: A new approach <i>C. Ronco</i>	17.18 Extracorporeal Therapies <i>T. Reis</i>	16.57 Extracorporeal Liver Support <i>M. Nadim</i>
17.18 PSP in bacterial superinfection in Covid-19 <i>F. Ventura</i>	17.03 Discussion	17.30 Discussion	17.09 Extracorporeal therapies: a view on the future <i>J. Cerda</i>
17.30 Discussion	17.15 SPONSORED ACTIVITY - 40' Symposium	17.45 SPONSORED ACTIVITY - 40' Symposium	17.21 Extracorporeal Lung Support <i>P. Navalesi</i>
17.45 SPONSORED ACTIVITY - 40' Symposium			17.33 Discussion
			17.45 SPONSORED ACTIVITY - 40' Symposium